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Factor H-Dependent Alternative Pathway Inhibition Mediated by
Porin B Contributes to Virulence of Neisseria meningitidis
Lisa A. Lewis,a David M. Vu,b Shreekant Vasudhev,a Jutamas Shaughnessy,a Dan M. Granoff,b Sanjay Rama
Division of Infectious Diseases and Immunology, University of Massachusetts Medical School, Worcester, Massachusetts, USAa; Center for Immunobiology and Vaccine
Development, Children’s Hospital Oakland Research Institute, Oakland, California, USAb
ABSTRACT The identification of “factor H binding protein (fHbp)-null” invasive meningococcal isolates and the realization that
widespread use of fHbp-based vaccines could herald selection of such strains prompted us to characterize novel mechanisms of
alternative pathway (AP) inhibition onmeningococci. Of seven strains engineered to lack four known AP-inhibiting molecules,
capsular polysaccharide, lipooligosaccharide sialic acid, fHbp, and neisserial surface protein A (quadruple mutants), four strains
inhibited human AP-mediated C3 deposition. All four expressed the porin B2 (PorB2) molecule, and three strains belonged to
the hypervirulent ST-11 lineage. Consistent with reduced C3 deposition, the rate of C3a generation by a PorB2 isolate was lower
than that by a PorB3 strain. Allelic replacement of PorB3 with PorB2, in both encapsulated and unencapsulated strains, con-
firmed the role of PorB2 in AP inhibition. Expression of PorB2 increased resistance to complement-dependent killing relative to
that seen in an isogenic PorB3-expressing strain. Adult rabbit andmouse APs were unimpeded on all mutants, and human fH
inhibited nonhuman C3 deposition on PorB2-expressing strains, which provided functional evidence for human fH-dependent
AP regulation by PorB2. Low-affinity binding of full-length human fH to quadruple mutants expressing PorB2 was demon-
strated. fH-like protein 1 (FHL-1; contains fH domains 1 through 7) and fH domains 6 and 7 fused to IgG Fc bound to one
PorB2-expressing quadruple mutant, which suggested that fH domains 6 and 7may interact with PorB2. These results associate
PorB2 expression with serum resistance and presage the appearance of fHbp-null and hypervirulent ST-11 isolates that may
evade killing by fHbp-based vaccines.
IMPORTANCE The widespread use of antimeningococcal vaccines based on factor H (fH) binding protein (fHbp) is imminent.
Meningococci that lack fHbp were recently isolated from persons with invasive disease, and these fHbp-null strains could spawn
vaccine failure. Our report provides a molecular basis for an explanation of how fHbp-null strains may evade the host immune
system. Meningococci possess several mechanisms to subvert killing by the alternative pathway (AP) of complement, including
production of the fHbp and NspA fH binding proteins. Here we show that a meningococcal protein called porin B2 (PorB2) con-
tributes to inhibition of the AP on the bacterial surface. A majority of the “fHbp-null” isolates identified, as well as all members
of a “hypervirulent” lineage (called ST-11), express PorB2. Our findings highlight the potential for the emergence of fHbp-
negative strains that are able to regulate the AP andmay be associated with fHbp vaccine failure.
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Neisseria meningitidis is an important cause of bacterial men-ingitis and sepsis worldwide. The complement system is an
important component of innate immune defenses against this
pathogen. Individuals deficient in terminal complement compo-
nents or in components of the alternative pathway (AP) are at an
increased risk of meningococcal disease (1). A key feature of the
AP of complement is a positive-feedback loop that amplifies C3b
deposition onmicrobial surfaces (2). The AP also plays an impor-
tant role in maximizing the killing activity elicited by select anti-
meningococcal antibodies (Abs) (3). Under physiological condi-
tions, factor H (fH) plays a major role in limiting unwanted
activation of the AP (4). fH acts as a cofactor for the factor
I-mediated cleavage of C3b to inactive C3b (iC3b) and also serves
to limit C3 activation by irreversibly dissociating the AP C3 con-
vertase (C3b, Bb). Microorganisms can hijack host fH and use
this molecule to protect themselves from immune attack by
downregulating deposition of C3b and inactivating C3b that is
deposited.
Themeningococcus possesses several distinct and often redun-
dant mechanisms to limit AP activation. Meningococci directly
bind human fH through two surface molecules, fH binding pro-
tein (fHbp) (5) and neisserial surface protein A (NspA) (6); both
serve to limit C3 deposition and enhance resistance of the organ-
ism to complement-dependent killing. In addition, sialylation of
meningococcal lacto-N-neotetraose (LNT) lipooligosaccharide
(LOS) regulates the AP by enhancing the interactions of the
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C-terminal domains of fH with surface-bound C3 fragments (7)
and the group B and group C capsular polysaccharides limit AP-
mediated deposition of C3 (8, 9).
Based on observations that binding of fH tomeningococci was
human specific (10), we developed a human fH transgenic (Tg) rat
which enhanced the ability of H44/76 to cause bacteremia (bacte-
remiawas observed after challengewith 5 102CFU) (11). Rather
unexpectedly, deleting both known fH ligands, fHbp, and NspA,
did not diminish the ability of H44/76 to cause bacteremia in
human fHTg infant rats (11); this result suggested the existence of
an additional human fH-dependent mechanism(s) for comple-
ment evasion. LOS sialylation was identified as one such mecha-
nism (7, 11).
Recent work by Lucidarme et al. (12) identifiedmeningococcal
isolates that lacked fHbp expression that had been collected from
patients with invasive disease, which demonstrated that in select
strains, fHbp was dispensable for virulence in humans. These
findings imply that certain meningococcal strains possess novel
means of inhibiting complement activation in the absence of
fHbp. This observation is particularly important given that fHbp-
based vaccines are on the verge of clinical use.
The aim of the present study was to identify novel mechanisms
meningococci use to regulate the AP that could contribute to the
virulence of this pathogen in the absence of fHbp. These mecha-
nisms could contribute to the ability of fHbp-negative meningo-
cocci tomaintain virulence and escape killing by fHbp-containing
vaccines.
RESULTS
Meningococcal PorB2 strains regulate the human AP. In order
to study AP regulation in the absence of factors known to modu-
late C3 deposition on meningococci, we created mutants that
lacked expression of capsular polysaccharide, LOS sialic acid,
fHbp, and NspA. Strains harboring these four mutations simulta-
neously are referred to here as “quadruple mutants.” Quadruple
mutants, derived from 7 diverse strains of N. meningitidis (see
Table S1 in the supplemental material), were screened for deposi-
tion of human C3 following incubation with normal human
serum-MgCl2-EGTA (NHS-Mg/EGTA) (20% [vol/vol]); Mg/
EGTA blocked classical and lectin pathway activation and allowed
assessment of AP activation only (Fig. 1). Significantly lower C3
deposition was seen on quadruple mutants generated from four
strains that expressed the PorB2 molecule than on mutants gen-
erated from strains that expressed PorB3 (Fig. 1A and B). Similar
results were seenwithC2-depleted serum (onlyAP intact; classical
and lectin pathways blocked) and with sera from two additional
donors (data not shown).
To ensure that serum factors other than AP components did
not contribute significantly to the differential C3 deposition on
the meningococcal mutants, we examined C3 deposition on the
strains using purified C3, factor B, factor D, and fH (Fig. 1C).
Again, each of the four PorB2-expressing quadruple mutants
showed significantly (P 0.01) lower C3 deposition than each of
the three PorB3 isolates. These data indicate that despite loss of
capsule, LOS sialic acid, fHbp, and NspA, select PorB2 strains
effectively regulated the human AP.
Decreased C3 deposition in PorB2 strains is associated with
slower C3 activation.Decreased C3 deposition could result from
reduced targets for covalent binding of C3 (i.e., fewer electron-
donating –OH groups) or decreased activation of C3 on the bac-
terial surface (i.e., because of increased fH binding) or a combi-
nation of these events. The quantitative differences seen by flow
cytometry (Fig. 1) were confirmed byWestern blotting (see Fig. S1
in the supplemental material), which revealed both LOS and Opa
as major targets for iC3b across all isolates, as has been previously
described forNeisseria (13). LOS structure canmodulate comple-
ment activation on neisseriae (7, 8, 14). All strains expressed an
~4.5-kDa LOS species; NZ98/254 showed an additional 3.6-kDa
LOS species (data not shown). Thus, there was no obvious corre-
lation between the LOS migration pattern and the amount of C3
deposited.
Activation of C3 is accompanied by release of the C3a frag-
ment, and measurement of the rate of C3a generation reflects C3
activation kinetics. Based on previously published data that mea-
sured the rates of complement activation (9), we focused on C3a
production during the first 15 min of incubation. Quadruple mu-
tants of 4243 (PorB2) and H44/76 (PorB3) were chosen as exam-
ples of low- and high-level C3 binders, respectively. As shown in
Fig. 1D, the reaction mixture containing the 4243 quadruple mu-
tant generated C3 at a rate lower than that seen with H44/76. The
total amounts of C3a in the reactionmixture reached similar levels
across strains at time points at or beyond 20min, likely becauseC3
convertases in the fluid phase contribute to overall complement
activation (9). These data suggest that lower C3 deposition on
strain 4243 occurs at least in part because of a lower rate of C3
activation.
Human fH regulates the AP of nonhuman complement on
PorB2-expressing quadruple mutants. Binding of fH to the
known meningococcal ligands for fH, fHbp, and NspA is human
specific (6, 10). To determine if regulation of the AP by PorB2-
bearing strains was also specific to humans, we measured deposi-
tion of rabbit and mouse C3 using adult sera. PorB2 did not reg-
ulate the AP of these adult animals, and similar amounts of C3
were deposited on all quadruple mutants (Fig. 2, black bars). The
addition of purified human fH to these nonhuman sera resulted in
significantly greater downregulation of the AP on PorB2 strains
relative to that seen with PorB3 isolates (Fig. 2, gray bars).
Fluorescence-activated cell sorter (FACS) tracings of a represen-
tative experiment are shown in Fig. S2 in the supplemental mate-
rial. These data provide strong evidence for human fH-dependent
regulation of the AP by PorB2-bearing strains compared to
PorB3-bearing strains.
Confirmation of the role of PorB2 in regulating the human
AP. PorB is a major outer membrane protein that contributes to
the fitness of a strain (15), and its deletion could have pleiotropic
effects with respect to bacterial growth in addition to any interac-
tions with the complement system. To avoid these concerns, we
created allelic exchanges of the entire porB2 and porB3 sequences
in a homologous background and compared C3 depositions in
these isogenic strains that differed only in PorB types. Two sets of
mutantswere created; the first set lacked fHbp,NspA, capsule, and
LOS sialic acid (H44/76 “quadruple”-PorB3 and H44/76
“quadruple”-PorB2), while the second set lacked fHbp and NspA
but elaborated capsule and sialylated LOS (H44/76 fHbp nspA-
PorB3 and H44/76 fHbp nspA-PorB2).
H44/76 that expressed PorB2 showed greater downregulation
of C3 deposition than H44/76 that expressed its own PorB3 mol-
ecule (Fig. 3). The effect was most pronounced in the absence of
capsule (Fig. 3A; “Cap”) but was also observed in the encapsu-
lated (Fig. 3C; “Cap”) background (quantitative comparisons
Lewis et al.
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are shown in Fig. 3B and D, respectively). These data provide
strong evidence for a role for PorB2 in regulating the human AP
on meningococci.
C3 deposition on PorB2-expressing strains displays a bimodal
distribution (Fig. 1B and 3A; see also Fig. S3 in the supplemental
material). These data suggest that there are two populations that
differentially regulate the AP. PorB2 expression was normally dis-
tributed (unimodal) and did not correlate with variation in C3
deposition. Regions of low, intermediate, and high PorB2 expres-
sion from within the normally distributed PorB2-positive popu-
lation all revealed bimodal C3 deposition (Fig. S3). Thus, mole-
cules other than PorB2 could contribute to the observed
heterogeneity in C3 deposition.
Binding of fH, fH/Fc fusion proteins, and fH-like protein 1
(FHL-1) to meningococci lacking fHbp and NspA. Having pro-
vided evidence for human fH-dependent downregulation of the
AP by PorB2-bearing strains, we compared the abilities of H44/76
“quadruple”-PorB3 and H44/76 “quadruple”-PorB2 to bind to
human fH. Using standard FACS analysis (Fig. 4A [see also
Fig. S4A in the supplemental material]; labeled “no cross-linker”)
and Western blot (data not shown) methods, we did not detect
binding of full-length human fH (100 g/ml) to either strain.
Similar negative results were obtained with the 7 quadruple mu-
tants that express either PorB2 (C2120, W171, 4243, and 2996) or
PorB3 (A2594, H44/76, and NZ98/254) (Fig. 4B [see also
Fig. S4B]; labeled “no cross-linker”). To enhance detection of low-
affinity interactions between fH and PorB, we added paraformal-
dehyde to cross-link bound fH to the bacterial surface prior to
washing and then detected bound fH by FACS analysis (the terms
“low” and “high” affinity are henceforth used to refer to low-level
fH binding that can be detected only with a cross-linker and high-
level fH binding that can be detected without a cross-linker). In
the presence of the cross-linker, the quadruple mutant of H44/76
expressing PorB2 bound greater amounts of fH than the isogenic
H44/76 bearing PorB3 (Fig. 4A [see also Fig. S4A]; labeled “para-
formaldehyde cross-linker”). In other experiments, quadruple
FIG 1 Regulation of the human AP by PorB2-expressing N. meningitidis. Seven strains of N. meningitidis that lacked capsular polysaccharide, LOS sialic acid,
and fHbp and NspA expression (quadruple mutants) were screened for AP-mediated C3 deposition with NHS-Mg/EGTA (20% [vol/vol]). (A) C3 deposition
measured by FACS analysis. The percentage of positive events relative to control organisms incubated with heat-inactivated serum (gated to yield 5% of positive
events in the negative-control sample as shown in Fig. 1B [ve]) is represented on the y axis. Each bar represents the standard error of the mean (SEM) of the
results of three independent experiments. ***, P 0.001 (1-way ANOVA with Tukey’s posttest for pairwise comparisons). (B) Histograms from an experiment
representative of those described for panel A; data represent the median fluorescence of C3 binding of the entire bacterial population. (C) AP regulation by
PorB2-expressing strains revealed using purified AP components. Quadruplemutants were incubated with purified C3 (500g/ml), factor B (100g/ml), factor
D (2g/ml), and factor H (100g/ml). C3b deposited on bacteria wasmeasured by FACS analysis. Controls were bacteria incubated with C3 alone. The amount
of deposited C3b is represented asmedian fluorescence (y axis). Each bar represents themean (range) of the results of two separate experiments. **, P 0.01. (D)
4243 (PorB2) activates the AP at a lower rate than H44/76 (PorB3). Quadruple mutants of 4243 (PorB2) and H44/76 (PorB3) were incubated with NHS-Mg/
EGTA. Supernatants collected at the times indicated (x axis) were assayed for C3a by enzyme-linked immunosorbent assay (ELISA). Each datumpoint represents
the SEM of the results of three independent experiments. **, P 0.01 (2-way ANOVA).
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mutants of 3 of 4 strains that expressed PorB2 (C2120,W171, and
4243) bound statistically significantly more fH than each of the 3
strains that expressed PorB3 (A2594, H44/76, andNZ98/254); the
fourth PorB2 strain, the quadruple mutant of 2996, also bound
more fH than strain H44/76 at a statistically significant level
(PorB3; P  0.05) (Fig. 4B [see also Fig. S4B]; labeled “parafor-
maldehyde cross-linker”). However, the higher fH binding by the
quadruple mutant of strain 2996 (PorB2) and each of the two
other PorB3-expressing strains was not statistically different (P
0.05).
Prior observations have shown that most pathogens interact
with fH domains 6 and 7 or domains 18 through 20 (16).Neisseria
that express fHbp (17) or NspA (6) bind fH67/Fc but not fH18-
20/Fc. Binding of two recombinant molecules that comprised ei-
ther fH domains 6 and 7 or fH domains 18 through 20 fused to
murine IgG2a Fc (fH67/Fc and fH18-20/Fc) to H44/76
“quadruple”-PorB3 and H44/76 “quadruple”-PorB2 demon-
strated that fH67/Fc specifically bound to H44/76 expressing
PorB24243 (Fig. 4C; gray-shaded histogram) but not to H44/76
expressing the homologous PorB3 molecule (Fig. 4C; red histo-
gram). The quadruple mutant of 4243, but not other strains (data
not shown), also bound fH67/Fc (Fig. 4C; green histogram). Bind-
ing of fH67/Fc to H44/76 “quadruple”-PorB2 (Fig. 4C; gray his-
togram) was decreased relative to binding of the quadruple mu-
tant of 4243 (Fig. 4C; green histogram), suggesting that the strain
background may be important for this interaction. fH18-20/Fc
did not bind to any quadruple mutant tested (data not shown).
N. meningitidis can also bind to fH-like protein 1 (FHL-1), a
molecule that contains the first seven N-terminal domains of fH
(18) and regulates the AP. Consistent with binding of fH67/Fc, the
quadruplemutant of 4243, but not other strains (data not shown),
bound purified FHL-1 (Fig. 4D). Binding of FHL-1 and fH67/Fc
to wild-type H44/76 expressing both fHbp and NspA is shown as
a positive control. All isolates expressed similar amounts of PorB
as assessed using Coomassie-stained gels, which suggested that
differences in PorB expression did not account for differences in
AP regulation or binding of FHL-1 or fH67/Fc (data not shown).
To better understand the differences in binding of FHL-1 and
fH67/Fc among the PorB2 isolates, the translated amino acid se-
quences were aligned (see Fig. S5 in the supplemental material).
The only difference between PorB2 of 4243, which bound FHL-1
and fH67/Fc with high affinity, and the PorB2 molecules of W171
and C2120, which did not, was the absence of a 3-amino-acid
stretch in predicted surface-loop 7 in the latter 2 strains (VKD
deleted in W171 and NGV deleted in C2120). The 4243 loop 7
sequence alone likely was not sufficient to mediate high-affinity
binding of fH67/Fc to PorB2, because the amino acid sequence of
loop 7 of PorB2 2996was identical to that of 4243; yet 2996 did not
bind detectable amounts of fH67/Fc in the absence of cross-linker.
Outside loop 7, the 2996 PorB2was themost divergent from 4243,
with 12 amino acid differences (see Fig. S5). The amino acid se-
quence of PorB2 4243 was identical to that of a group C strain
called FAM18; a quadruplemutant of FAM18 also bound fH67/Fc
and regulated the human AP (see Fig. S6 in the supplemental
material). This observation further supports the idea of a role of
PorB2 in regulating the AP.
All PorB2 strains tested regulated the AP (Fig. 1), and in all
cases this regulation was dependent on the presence of human fH
(Fig. 2). All PorB2-expressing strains bound full-length fHwhen a
cross-linker was used to detect low-affinity binding, and 4243
bound FHL-1 with high affinity in the absence of a cross-linker.
Collectively, these data suggest that AP regulation by human fH
involves low-affinity PorB2-fH interactions.
Expression of PorB2 enhances serum resistance. To deter-
mine the relative roles of PorB2 and PorB3 in serum resistance, we
compared the abilities of H44/76 fHbp nspA-PorB3 and H44/76
fHbp nspA-PorB2 to resist killing by human serum. Strains lacking
fHbp and NspA were used to avoid the confounding effects of fH
binding to these ligands. Serumwas absorbed against a mixture of
H44/76 fHbp nspA-PorB3 and H44/76 fHbp nspA-PorB2 to re-
move strain-specific antibodies. Absorbed serum (20%) alone did
not kill either strain (Fig. 5). Expression of PorB2 by H44/76 fHbp
nspA resulted in greater resistance to complement-dependent kill-
ingmediated by anti-group B capsule IgG antibody SEAM12 (19)
FIG 2 Human fH inhibits C3 deposition by adult nonhuman complement on
PorB2-expressing quadruple mutants. Quadruple mutants of 7 strains of
N. meningitidis were incubated with adult rabbit complement (A) or adult
mouse serum (B) in either the absence (“”; solid black bars) or the presence
(“”; gray bars) of human fH (80g/ml), and levels ofC3 fragments deposited
on bacteria were measured by FACS analysis. The control (open bar) repre-
sents C3 deposition when bacteria were incubated with heat-inactivated com-
plement. The percentage of positive events relative to controls (bacteria plus
heat-inactivated complement) is shown on the y axis. Each bar represents the
SEM of the results of 2 to 3 independent observations. **, P 0.01; ***, P
0.001 (1-way ANOVA).
Lewis et al.
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than expression of PorB3 (Fig. 5). Absorbed serum treated with
Mg/EGTA to selectively activate the AP did not initiate killing of
either strain in the presence or absence of SEAM 12 (100% sur-
vival in both instances). As previously reported for other antime-
ningococcal Abs (3), the AP was required for maximal killing;
blocking the AP with an anti-factor Bb monoclonal antibody
(MAb) decreased killing of H44/76 fHbp nspA-PorB2 (SEAM 12
[1 g/ml] plus absorbed serum yielded 35% survival versus 71%
survival when anti-Bb blocked the AP; P 0.01). These data cor-
relate expression of PorB2with the evasion of immune killing seen
when all pathways of complement were intact.
DISCUSSION
PorB, one of the most abundant proteins in the neisserial outer
membrane, is an integral membrane protein organized as a  bar-
rel with 16 transmembrane domains and 8 predicted surface loops
(20). PorB functions as a porin, allowing the passage of small
molecules across the outer membrane, and has also been impli-
cated in virulence. Gonococcal PorB has been shown to play a key
role in regulation of both the AP and classical pathways of com-
plement by virtue of its ability to bind to fH and C4BP, respec-
tively (21, 22). Meningococcal PorB is divided into two classes,
PorB2 and PorB3, which are mutually exclusive and are expressed
FIG 3 PorB2 mediates regulation of the human AP. Isogenic strains that differed only in PorB expression (either PorB3H44/76 or PorB24243) were created in
H44/76. All mutants lacked fHbp andNspA and were either unencapsulated with no LOS sialic acid (“quadruple”; “Cap”) or possessed a capsule and LOS acid
(H44/76 fHbp nspA-PorB3 and H44/76 fHbp nspA-PorB2; “Cap”). Bacteria were incubated with NHS-Mg/EGTA (20% [vol/vol]), and C3 deposited on the
bacterial surface was measured by FACS analysis. (A and C) Representative histogram tracings of C3 deposition on the unencapsulated (Cap-) and encapsulated
(Cap) strains. Bacteria incubated with heat-inactivated serum served as negative controls (dashed lines). (B andD)Quantitative representation (percentage of
positive events on the y axis; mean [SEM] of the results of three independent experiments) of C3 deposition on the Cap- and Cap isogenic PorB mutants,
respectively. The percentage of positive events relative to control organisms incubated with heat-inactivated serum (gated to yield 5% of positive events in the
negative-control sample as shown in Fig. 1B [ve]) is represented on the y axis. Wild-type parent strains H44/76 and 4243 are shown as comparators. Note the
different y-axis scales in panels B and D. ***, P 0.001; **, P 0.01.
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from alternate alleles (porB2 and porB3) at the porB locus. PorB3
ofN.meningitidis serves as a ligand for Toll-like receptor 2 (TLR2)
and activates cells through a TLR2/TLR1-dependent pathway
(23).
The goal of our study was to examine AP regulation in strains
that did not rely on fHbp or NspA expression. We have identified
a novel role for meningococcal PorB2 in regulation of the AP of
complement. Concurrent with our studies, Lucidarme and col-
leagues described 29 invasive meningococcal isolates that lacked
fHbp expression (12). Of these strains, nine belonged to the “hy-
pervirulent” ST-11 lineage. It is noteworthy that strains that be-
long to the hypervirulent ST-11 clonal complex express PorB2. In
an ongoing analysis of select strains reported by Lucidarme et al.,
three of four non-ST-11 isolates also expressed PorB2 (24). Al-
though anti-capsule MAb SEAM 12 could overcome AP regula-
tion and initiate in vitro killing of meningococci, maximal killing
required the AP. Further, our studies demonstrated that expres-
sion of PorB2, relative to PorB3, enhanced the ability of H44/76
fHbp nspA to evade complement-mediated killing. Similarly,
expression of PorB2 may render strains more resistant to
complement-dependent killing in humans. The ability to regulate
complement and cause invasive disease in the absence of fHbp
expressionmay offer these strains a distinct advantage when faced
with immune pressure by anti-fHbp antibodies, which is a likely
occurrence with clinical use of fHbp-containing vaccines (25, 26).
Natural disruption of PorA (27, 28) and NadA (IS1301) (29),
which are both components of the proposed vaccine, has also been
reported in the ET-15 subset of the ST-11 complex.
FIG 4 PorB2 binds full-length fH, fH domains 6 and 7, and FHL-1. (A and B) Binding of human fH to quadruple mutants of H44/76 that express either
PorB344/76 (H44/76-PorB3) or PorB24243 (H44/76-PorB2) (A) and quadruple mutants ofN. meningitidis strains that express either PorB3 (A2594, H44/76, and
NZ98/254) or PorB2 (C2120, W171, 4243, and 2996) (B). Quadruple mutants were incubated with purified fH (100 g/ml), and bound fH was measured by
FACS analysis (graphs labeled “no cross-linker”). In some experiments, bound fH was cross-linked to the surface with paraformaldehyde (final concentration,
1% [vol/vol]) prior to detection by FACS analysis (graphs labeled “paraformaldehyde cross-linker”). The negative control (control) was a reaction mixture that
lacked fH (neg. control). Binding of fH towild-typeH44/76 that expresses fHbp, NspA, capsule, and LOS sialic acid is shown as a positive control in panel B (pos.
control). The amount of bound fH is represented on the y axis as fold change in median fluorescence relative to the H44/76 quadruple mutant that expresses
PorB3 (in panel A) or the H44/76 quadruple mutant (in panel B) with paraformaldehyde cross-linker. Each bar represents the SEM of the results of 2 to 3
independent experiments (note that some error bars are small and are not easily seen on the figure). **,P 0.01; *,P 0.05 (1-wayANOVAwithTukey’s posttest
for pairwise comparisons). (C) PorB24243 binds to fH67/Fc. Binding of human fH67/Fc to quadruple mutants of H44/76 (blue line), 4243 (green line), and
H44/76 that express either PorB344/76 (H44/76-PorB3; red line) or PorB24243 (H44/76-PorB2; gray shading)wasmeasured by FACS analysis. The negative control
(broken line) was a reaction mixture that lacked fH67/Fc. x axis, fluorescence on a log10 scale; y axis, counts. Data from an experiment representative of at least
two reproducible repeats are shown. (D) A quadruple mutant of strain 4243 binds FHL-1. Binding of FHL-1 (10 g/ml) to the 4243 quadruple mutant
(gray-shaded histogram) was measured by FACS analysis using polyclonal goat anti-human fH. FHL-1 was omitted in the negative control (broken line). The
positive control shows binding of FHL-1 to wild-type H44/76 (solid black line). Numbers alongside histograms represent the median fluorescence, and the
fill/outline corresponds to that of the histograms.
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Wehave provided considerable functional evidence for human
fH-dependent inhibition of the AP by PorB2. A novel finding of
this study was the low affinity of the interaction between full-
length fH and PorB2 on intact bacteria. fH is present in serum at
concentrations of 200 to 500 g/ml (~1.3 to 3.3 M), and, given
these high ligand concentrations, it is plausible that low-affinity
interactions between PorB2 and fH suffice for complement inhi-
bition. Higher-affinity fH-ligand interactions may be important
in niches where the concentration of fH is lower, such as at mu-
cosal surfaces. Several studies have highlighted a lack of correla-
tion between the amount of fH binding to meningococci as re-
vealed by flow cytometry and complement inhibition on the
bacterial surface. Seib et al. (30) and Dunphy et al. (31) have
shown that neither differences in fHbp-fH affinity (over 2 orders
of magnitude) nor differences in the amount of fH bound to bac-
teria by FACS predicted resistance to complement-dependent
killing. Another example is the NspA-fH interaction; despite the
fact that capsule and full-length LOS expression decreased fH
binding to NspA to levels barely detectable by FACS analysis,
complement-inhibiting function was demonstrated under these
circumstances (6). As an additional point, we previously demon-
strated that a H44/76 mutant lacking fHbp and NspA, which did
not bind human fH at detectable levels in vitro, caused bacteremia
in human fH transgenic, but not wild-type, infant rats. These data
highlighted the in vivo significance of fH function even in the
absence of high-affinity fH binding in vitro (11). This “double”
fHbp NspAmutant was also sensitive to infant rat complement in
vitro, but dose-responsive resistance was observed upon addition
of human fH (11). The paradigm for studying regulation of the AP
may shift from relying on demonstration of high-affinity binding
of fH to examining more functional readouts of complement ac-
tivation (such as, downregulation of C3 deposition).
We were able to demonstrate high-affinity binding of FHL-1
and fH67/Fc to strains expressing PorB4243. These findings were
confirmed in strain FAM18, which expresses a PorB2 with an
amino acid sequence identical to that of 4243. High-affinity bind-
ing of these “fragments” of fH, but not the full-length fH, to
strains expressing PorB4243 may result from structural constraints
in intact fH (32, 33) that reduce its affinity for intact bacteria. A
more detailed understanding of the regions of PorB that are re-
quired for functional interactions with fH may aid in the predic-
tion of specific PorB molecules that may be involved in comple-
ment evasion.
This report sheds light on an important immune evasion func-
tion mediated by meningococcal PorB. In light of the functional
role of PorB in complement evasion, it is conceivable that imple-
mentation of fHbp-containing vaccines (25, 26) may drive (or
select for) loss of fHbp expression in combination with positive
selection for specific PorB molecules that are optimized for AP
regulation and functional interaction with fH.
MATERIALS AND METHODS
Ethics statement. This study was approved by the Committee for the
Protection of Human Subjects in Research at the University ofMassachu-
setts Medical School. All subjects who donated blood for this study pro-
vided written informed consent.
Bacterial strains and culture conditions. Characteristics of the wild-
type strains used to derive the mutants used in this study are listed in
Table S1 in the supplemental material.N. meningitidis bacteria were rou-
tinely grown on chocolate agar plates supplemented with IsoVitaleX
equivalent at 37°C in an atmosphere with 5% CO2. GC plates supple-
mented with IsoVitaleX equivalent were used for antibiotic selection.
Escherichia coli bacteria (Invitrogen, Carlsbad, CA) were cultured in
Luria-Bertani broth or agar with antibiotics as needed. Antibiotics were
used at the concentrations indicated in Table S2 in the supplemental ma-
terial.
Strains were rendered unencapsulated by interruption of mynB
(group A) or siaD (group B, C, or W135) (6, 34). Insertional inactivation
of lst (lst::kan) abrogated LOS sialylation of group B, C, andW135 isolates
as previously described (6, 34). Group A strains do not sialylate their LOS
unless cytidinemonophospho-N-acetylneuraminic acid (CMP-NANA) is
added to growthmedia. fHbp andNspA expressionwas abrogated (fHbp::
erm [5] and nspA::spc [6], respectively) as previously described.
PorB deletion mutants of H44/76 fHbp nspAwere constructed using a
plasmid that contained (5= to 3=) an 800-bp region 5= to PorB3H44/76
(amplified with porMC58up_F_ApaI and porMC58up_R_SacII; see Ta-
ble S3 in the supplemental material), the AphA3 kanamycin resistance
determinant, and a 1,100-bp region 3= to PorB3H44/76 (amplified with
PorMC58Down_F_SpeI and PorMC58Down_R_SacI; see Table S3). Me-
ningococcal strains were transformed as previously described.
PorB allelic replacements in H44/76 were made using the H44/76
PorB3 deletion strain and chromosomal DNA isolated from either 4243
or H44/76 containing the TetM tetracycline resistance cassette down-
stream of porB2 or porB3, respectively. This ensured complete replace-
ment of porB and eliminated the potential formation of hybrid PorB2/
PorB3 molecules. TetM was inserted downstream of porB in each strain
using plasmids that contained either porB3H44/76 (amplified with
MC58_porB3R_SacII and MC58_porB3F_ApaI; see Table S3 in the sup-
plemental material) or porB24243 (amplified with FAM18_porB2F_ApaI
and Nl_porR_SacII; see Table S3) followed by TetM and the 1,100-bp
region 3= to porB3H44/76 described above. Transformants were selected for
tetracycline resistance and checked for sensitivity to kanamycin. All clones
were verified by DNA sequencing.
Sera. Normal human serum (NHS) was obtained from healthy adult
volunteers, divided into aliquots, and stored (as individual sera) at80°C
till used. To inactivate selectively the classical and lectin complement
FIG 5 PorB2 expression enhances serum resistance. Data represent percent
survival of isogenic H44/76 fHbp nspA expressing either PorB24243 (PorB2;
open bar) or PorB3H44/76 (PorB3; gray bar) in 20% absorbed serum that con-
tained anti-group B capsule antibody, SEAM 12, at the concentrations indi-
cated. Heat-inactivated (HI) sera andNHSwithout added SEAM12 (0g/ml)
served as controls. Percent survival relative to time 0 is plotted on the y axis.
Each bar represents the SEM of the results of three independent observations.
**, P 0.01; ****, P 0.0001 (2-way ANOVA).
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pathways and isolate the AP as the only active pathway, MgCl2 and EGTA
(10 mM each) were added to NHS (NHS-Mg/EGTA).
Absorbed sera, in which antibodies specific to H44/76 fHbp nspA
PorB3 and H44/76 fHbp nspA PorB2 were removed, were prepared as
follows. EDTA (10 mM) was added to fresh NHS, and the sera were dia-
lyzed against phosphate-buffered saline (PBS)–1mMEDTA for 4 h at 4°C
using a 10-kDa molecular mass cutoff. Meningococcal strains were sub-
jected to passage on overnight plates and added onto fresh chocolate agar
plates and grown for 5 h. Bacteria were harvested and washed once with
PBS–1 mM EDTA. Dialyzed serum was absorbed twice with bacteria
(1-ml serum with a mixture of 100 l of packed cells from each of the 2
mutant strains) processed end over end for 30 min at 4°C. The serumwas
filtered (0.22-m-pore-size filter), divided into aliquots, and stored at
80°C. Ca2 and Mg2 (2 mM each) were added prior to use. Similar
amounts of fH were detected (MAb 90X) in NHS and absorbed sera spot-
ted on polyvinylidene difluoride (PVDF), which suggested that the fHwas
not depleted by the absorption. The hemolytic activity of serum was con-
firmed using a Total hemolytic complement kit.
Mouse complement was obtained by cardiac puncture of adult
BALB/c mice. Blood was allowed to clot at 22°C for 20 min, followed by
incubation at 4°C for 20 min, and then spun, and the supernatant was
divided into aliquots and stored at80°C. Adult rabbit complement was
purchased from Cedarlane Laboratories.
Bacterial killing by NHS. Susceptibility of neisserial strains to
complement-mediated killing was determined using a serum bactericidal
assay as described previously (6). Anti-group B capsule IgG antibody
SEAM12 (19) was added to absorbed sera at the concentrations indicated.
Survival was calculated as the number of viable colonies at time 30 min
relative to time 0.
Purified complement components. Factors B andDwere fromCom-
plement Technology, Inc. (Tyler, TX). C3 was isolated from human
plasma by polyethylene glycol (PEG) precipitation and chromatography
over DEAE Sephacel using amodification of previously establishedmeth-
ods (35). NHS immunodepleted of C3 (Complement Technology, Inc.)
regained full hemolytic activity upon addition of the purified C3 to a
concentration of 500g/ml, using aTotal hemolytic complement kit (The
Binding Site, Birmingham, United Kingdom).
C3 deposition on bacteria using purified complement proteins. To
deposit C3 on bacteria using purified AP components, ~108 bacteria in
Hanks balanced salt solution (HBSS)–1 mM MgCl2–0.1% bovine serum
albumin (BSA) were incubated with C3 (500 g/ml), factor B (100 g/
ml), and fH (100g/ml) followed by factor D (2g/ml) in a final reaction
volume of 50l for 30 min at 37°C. Deposited C3 was measured by FACS
analysis.
Antibodies.Human, rabbit, andmouseC3 deposition on bacteria was
measured using fluorescein isothiocyanate (FITC)-conjugated anti-
human C3 (BioDesign/Meridian Life Sciences), anti-guinea pig C3, and
anti-mouse C3 (the latter 2 from Cappel/MP Biomedical) at a dilution of
1:200 in HBSS–0.1% BSA, respectively. Preliminary FACS and Western
blotting experiments confirmed the specificity and cross-reactivity of
anti-guinea pig C3 FITC with rabbit C3.
Recombinant human fH/Fc fusion proteins. fH domains 18 through
20 fused in frame to the N terminus of the Fc fragment of murine IgG2a
(called fH/Fc) have been described previously (36). Similarly, we gener-
ated fH domains 6 and 7 fused to murine IgG2a Fc. fH domains 6 and 7
were amplified (primers, six AscI and seven NotI) from human fH cDNA
(gift ofM. K. Pangburn, University of Texas Health Science Center, Tyler,
TX) and cloned into AscI and NotI sites of pcDNA3 (Invitrogen Life
Technologies) encoding mouse IgG2a Fc (37). Transfection of CHO cells
and protein purification using protein A Sepharose were performed as
described previously (36).
Flow cytometry. Human, rabbit, and mouse C3 deposition on the
bacterial surface and FHL-1, fH, and fH/Fc construct binding were mea-
sured using flow cytometry as described previously (10, 17, 36). To detect
low-affinity binding of fH, organisms incubated with human fH (100g/
ml) for 30 min were fixed by the addition of paraformaldehyde (final
concentration, 1%). The organisms were pelleted after incubation for
10 min at room temperature, and bound fH was detected by flow cytom-
etry as described above. Data were analyzed using FlowJo (version 7.2.5;
Tree Star, Inc.). Binding is represented either as a percentage of positive
events (relative to a negative control that was gated to yield 5% of positive
events) when histogram tracings showed a non-Gaussian distribution or
asmedian fluorescence of the entire bacterial populationwhen all samples
yielded normally distributed histograms.
C3 generation assay. Bacteria (~2  108) were incubated with 20%
NHS-Mg/EGTA in an initial reaction volume of 200 l. Samples (10 l)
were collected at specified intervals between 0min and 15min and diluted
immediately in 90l PBS–50mMEDTA. C3a in the reactionmixture was
measured using a MicroVueC3a Plus EIA kit (Quidel) according to the
manufacturer’s instructions.
Statistical analyses. Statistical comparisons across multiple groups
were carried out using 1-way analysis of variance (ANOVA) with Tukey’s
posttest for pairwise comparisons. Differences in C3a generation and bac-
terial survival between strains were measured using 2-way ANOVA with
Bonferroni’s posttest. All probability values, with the exception of the
1-way ANOVA, are two tailed.
SUPPLEMENTAL MATERIAL
Supplemental material for this article may be found at http://mbio.asm.org
/lookup/suppl/doi:10.1128/mBio.00339-13/-/DCSupplemental.
Figure S1, TIF file, 0.4 MB.
Figure S2, TIF file, 0.4 MB.
Figure S3, TIF file, 1 MB.
Figure S4, TIF file, 0.4 MB.
Figure S5, TIF file, 1 MB.
Figure S6, TIF file, 0.4 MB.
Table S1, DOCX file, 0.1 MB.
Table S2, DOCX file, 0.1 MB.
Table S3, DOCX file, 0.1 MB.
ACKNOWLEDGMENTS
This work was supported by grants AI054544, AI084048, AI32725, AI
046464, and AI 082263 from the National Institute of Allergy and Infec-
tious Diseases, NIH. The work at the Children’s Hospital Oakland Re-
search Institute was performed in a facility funded by Research Facilities
Improvement Program grant number C06 RR 016226 from the National
Center for Research Resources, NIH.
We thank Ulrich Vogel (Universität Würzburg, Germany) for A2594,
H44/76, C2120, and W171 and their mutants lacking capsule and LOS
sialic acid.
REFERENCES
1. Ram S, Lewis LA, Rice PA. 2010. Infections of people with complement
deficiencies and patients who have undergone splenectomy. Clin. Micro-
biol. Rev. 23:740–780.
2. Austen KF, Fearon DT. 1979. A molecular basis of activation of the
alternative pathway of human complement. Adv. Exp. Med. Biol. 120B:
3–17.
3. Giuntini S, Reason DC, Granoff DM. 2012. The combined roles of
human IgG subclass, alternative complement pathway activation, and
epitope density on bactericidal activity of antibodies to meningococcal
factor H binding protein. Infect. Immun. 80:187–194.
4. Ferreira VP, Pangburn MK, Cortés C. 2010. Complement control pro-
tein factor H: the good, the bad, and the inadequate. Mol. Immunol.
47:2187–2197.
5. Madico G, Welsch JA, Lewis LA, McNaughton A, Perlman DH, Costello
CE, Ngampasutadol J, Vogel U, Granoff DM, Ram S. 2006. The menin-
gococcal vaccine candidate GNA1870 binds the complement regulatory
protein factor H and enhances serum resistance. J. Immunol. 177:
501–510.
6. Lewis LA, Ngampasutadol J, Wallace R, Reid JE, Vogel U, Ram S. 2010.
Themeningococcal vaccine candidate neisserial surface protein A (NspA)
Lewis et al.
8 ® mbio.asm.org September/October 2013 Volume 4 Issue 5 e00339-13
binds to factor H and enhances meningococcal resistance to complement.
PLoS Pathog. 6:e1001027.
7. Lewis LA, Carter M, Ram S. 2012. The relative roles of factor H binding
protein, neisserial surface protein A, and lipooligosaccharide sialylation in
regulation of the alternative pathway of complement on meningococci. J.
Immunol. 188:5063–5072.
8. Jarvis GA, Vedros NA. 1987. Sialic acid of group B Neisseria meningitidis
regulates alternative complement pathway activation. Infect. Immun. 55:
174–180.
9. Ram S, Lewis LA, Agarwal S. 2011. Meningococcal group W-135 and Y
capsular polysaccharides paradoxically enhance activation of the alterna-
tive pathway of complement. J. Biol. Chem. 286:8297–8307.
10. Granoff DM, Welsch JA, Ram S. 2009. Binding of complement factor H
(fH) to Neisseria meningitidis is specific for human fH and inhibits com-
plement activation by rat and rabbit sera. Infect. Immun. 77:764–769.
11. Vu DM, Shaughnessy J, Lewis LA, Ram S, Rice PA, Granoff DM. 2012.
Enhanced bacteremia in human factor H transgenic rats infected byNeis-
seria meningitidis. Infect. Immun. 80:643–650.
12. Lucidarme J, Tan L, Exley RM, Findlow J, Borrow R, Tang CM. 2011.
Characterization of Neisseria meningitidis isolates that do not express the
virulence factor and vaccine antigen factor H binding protein. Clin. Vac-
cine Immunol. 18:1002–1014.
13. Lewis LA, Ram S, Prasad A, Gulati S, Getzlaff S, Blom AM, Vogel U,
Rice PA. 2008. Defining targets for complement components C4b and
C3b on the pathogenic neisseriae. Infect. Immun. 76:339–350.
14. Ram S, Cox AD, Wright JC, Vogel U, Getzlaff S, Boden R, Li J, Plested
JS, Meri S, Gulati S, Stein DC, Richards JC, Moxon ER, Rice PA. 2003.
Neisserial lipooligosaccharide is a target for complement component C4b:
inner core phosphoethanolamine residues define C4b linkage specificity.
J. Biol. Chem. 278:50853–50862.
15. Nawar H, Smith K, Amer L, Vann W, Bash M. 2012. Analysis of the
effect of antigenic diversity of the Neisseria meningitidis outer membrane
porin B protein (PorB) on strain fitness, p 202. In Frosch M, Rudel T,
Vogel U (ed), XVIIIth International Pathogenic Neisseria Conference.
Wuerzburg, Germany. Conventus Congressmanagement and Marketing
GmbH, Jena, Germany.
16. Blom AM, Hallström T, Riesbeck K. 2009. Complement evasion strate-
gies of pathogens—acquisition of inhibitors and beyond. Mol. Immunol.
46:2808–2817.
17. Shaughnessy J, Lewis LA, Jarva H, Ram S. 2009. Functional comparison
of the binding of factor H short consensus repeat 6 (SCR 6) to factor H
binding protein from Neisseria meningitidis and the binding of factor H
SCR 18 to 20 to Neisseria gonorrhoeae porin. Infect. Immun. 77:
2094–2103.
18. Zipfel PF, Skerka C. 1999. FHL-1/reconnection: a human complement
and immune regulator with cell-adhesive function. Immunol. Today 20:
135–140.
19. Granoff DM, Bartoloni A, Ricci S, Gallo E, Rosa D, Ravenscroft N,
Guarnieri V, Seid RC, Shan A, Usinger WR, Tan S, McHugh YE, Moe
GR. 1998. Bactericidal monoclonal antibodies that define unique menin-
gococcal B polysaccharide epitopes that do not cross-react with human
polysialic acid. J. Immunol. 160:5028–5036.
20. Tanabe M, Nimigean CM, Iverson TM. 2010. Structural basis for solute
transport, nucleotide regulation, and immunological recognition ofNeis-
seria meningitidis PorB. Proc. Natl. Acad. Sci. U. S. A. 107:6811–6816.
21. Ram S, Cullinane M, Blom AM, Gulati S, McQuillen DP, Monks BG,
O’Connell C, Boden R, Elkins C, Pangburn MK, Dahlbäck B, Rice PA.
2001. Binding of C4b-binding protein to porin: amolecularmechanismof
serum resistance of Neisseria gonorrhoeae. J. Exp. Med. 193:281–296.
22. Ram S, McQuillen DP, Gulati S, Elkins C, Pangburn MK, Rice PA.
1998. Binding of complement factor H to loop 5 of porin protein 1A: a
molecular mechanism of serum resistance of nonsialylated Neisseria gon-
orrhoeae. J. Exp. Med. 188:671–680.
23. Massari P, Visintin A, Gunawardana J, Halmen KA, King CA, Golen-
bock DT, Wetzler LM. 2006. Meningococcal porin PorB binds to TLR2
and requires TLR1 for signaling. J. Immunol. 176:2373–2380.
24. Giuntini S, Vu DM, Granoff DM. 2013. fH-dependent complement
evasion by disease-causing meningococcal strains with absent fHbp genes
or frameshift mutations. Vaccine 31:4192–4199.
25. Nissen MD, Marshall HS, Richmond PC, Jiang Q, Harris SL, Jones TR,
Jansen KU, Perez JL. 2013. A randomized, controlled, phase 1/2 trial of a
Neisseria meningitidis serogroup B bivalent rLP2086 vaccine in healthy
children and adolescents. Pediatr. Infect. Dis. J. 32:364–371.
26. Santolaya ME, O’Ryan ML, Valenzuela MT, Prado V, Vergara R,
Muñoz A, Toneatto D, Graña G, Wang H, Clemens R, Dull PM,
V72P10 Meningococcal B Adolescent Vaccine Study Group. 2012. Im-
munogenicity and tolerability of a multicomponent meningococcal sero-
group B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3
randomised, observer-blind, placebo-controlled study. Lancet 379:
617–624.
27. Jelfs J, Munro R, Wedege E, Caugant DA. 2000. Sequence variation in
the porA gene of a clone ofNeisseria meningitidis during epidemic spread.
Clin. Diagn. Lab. Immunol. 7:390–395.
28. Van der Ende A, Hopman CT, Dankert J. 1999. Deletion of porA by
recombination between clusters of repetitive extragenic palindromic se-
quences in Neisseria meningitidis. Infect. Immun. 67:2928–2934.
29. Elias J, Vogel U. 2007. IS1301 fingerprint analysis of Neisseria meningiti-
dis strains belonging to the ET-15 clone. J. Clin. Microbiol. 45:159–167.
30. Seib KL, Brunelli B, Brogioni B, Palumbo E, Bambini S, Muzzi A,
DiMarcello F, Marchi S, van der Ende A, Aricó B, Savino S, Scarselli M,
Comanducci M, Rappuoli R, Giuliani MM, Pizza M. 2011. Character-
ization of diverse subvariants of the meningococcal factor H (fH) binding
protein for their ability to bind fH, to mediate serum resistance, and to
induce bactericidal antibodies. Infect. Immun. 79:970–981.
31. Dunphy KY, Beernink PT, Brogioni B, Granoff DM. 2011. Effect of
factor H-binding protein sequence variation on factor H binding and
survival of Neisseria meningitidis in human blood. Infect. Immun. 79:
353–359.
32. Makou E, Mertens HD, Maciejewski M, Soares DC, Matis I, Schmidt
CQ, Herbert AP, Svergun DI, Barlow PN. 2012. Solution structure of
CCP modules 10–12 illuminates functional architecture of the comple-
ment regulator, factor H. J. Mol. Biol. 424:295–312.
33. Okemefuna AI, Nan R, Gor J, Perkins SJ. 2009. Electrostatic interactions
contribute to the folded-back conformation of wild type human factor H.
J. Mol. Biol. 391:98–118.
34. Madico G, Ngampasutadol J, Gulati S, Vogel U, Rice PA, Ram S. 2007.
Factor H binding and function in sialylated pathogenic neisseriae is influ-
enced by gonococcal, but not meningococcal, porin. J. Immunol. 178:
4489–4497.
35. Hammer CH, Wirtz GH, Renfer L, Gresham HD, Tack BF. 1981. Large
scale isolation of functionally active components of the human comple-
ment system. J. Biol. Chem. 256:3995–4006.
36. Ngampasutadol J, Ram S, Gulati S, Agarwal S, Li C, Visintin A, Monks
B, Madico G, Rice PA. 2008. Human factor H interacts selectively with
Neisseria gonorrhoeae and results in species-specific complement evasion.
J. Immunol. 180:3426–3435.
37. Visintin A, Halmen KA, Latz E, Monks BG, Golenbock DT. 2005.
Pharmacological inhibition of endotoxin responses is achieved by target-
ing the TLR4 coreceptor, MD-2. J. Immunol. 175:6465–6472.
Complement Regulation by Meningococcal PorB
September/October 2013 Volume 4 Issue 5 e00339-13 ® mbio.asm.org 9
